Glucagon-like peptide-1 receptor agonists and muscle mass effects
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085818" target="_blank" >RIV/00023001:_____/25:00085818 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11310/25:10515663
Výsledek na webu
<a href="https://www.sciencedirect.com/science/article/pii/S1043661825003524?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1043661825003524?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.phrs.2025.107927" target="_blank" >10.1016/j.phrs.2025.107927</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Popis výsledku v původním jazyce
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests that these agents may also contribute to an unintended reduction in skeletal muscle mass, potentially exacerbating or precipitating sarcopenic obesity, particularly in older or frail individuals with limited muscular reserves. This review critically examines current data on the effects of GLP-1 RAs on body composition, explores the underlying pathophysiological mechanisms of skeletal muscle wasting, and offers evidence-based strategies for attenuating these potential adverse outcomes. While GLP-1 RAs therapy remains central to obesity management, optimizing its use through early recognition and management of associated risks is essential to preserve muscular health, patient functional status and quality of life.
Název v anglickém jazyce
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Popis výsledku anglicky
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests that these agents may also contribute to an unintended reduction in skeletal muscle mass, potentially exacerbating or precipitating sarcopenic obesity, particularly in older or frail individuals with limited muscular reserves. This review critically examines current data on the effects of GLP-1 RAs on body composition, explores the underlying pathophysiological mechanisms of skeletal muscle wasting, and offers evidence-based strategies for attenuating these potential adverse outcomes. While GLP-1 RAs therapy remains central to obesity management, optimizing its use through early recognition and management of associated risks is essential to preserve muscular health, patient functional status and quality of life.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Pharmacological research
ISSN
1043-6618
e-ISSN
1096-1186
Svazek periodika
220
Číslo periodika v rámci svazku
October 2025
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
19
Strana od-do
"art. no. 107927"
Kód UT WoS článku
001561951000001
EID výsledku v databázi Scopus
2-s2.0-105014122899